Loading organizations...
Loading organizations...
Developing fully human monoclonal antibody therapeutics for diseases.
Kymab has raised $229.9M across 5 funding rounds.
Kymab has raised $229.9M in total across 5 funding rounds.
Kymab has raised $229.9M in total across 5 funding rounds.
Kymab's investors include Melanie Lee, Bill & Melinda Gates Foundation, Simone Song, CF Woodford Equity Income Fund, Malin Corporation, Shenzhen Hepalink Pharmaceutical, Woodford Patient Capital Trust, Adrian Howd.
Kymab has raised $229.9M across 5 funding rounds. Most recently, it raised $30.0M Other Equity in June 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 24, 2019 | $30.0M Other Equity | Melanie Lee | |
| Jan 10, 2017 | $9.0M Grant | Bill & Melinda Gates Foundation | |
| Nov 24, 2016 | $100.9M Series C | Simone Song | Bill & Melinda Gates Foundation, CF Woodford Equity Income Fund, Malin Corporation, Shenzhen Hepalink Pharmaceutical, Woodford Patient Capital Trust |
| May 6, 2015 | $50.0M Series B Extension | Adrian Howd, Woodford Patient Capital Trust | |
| May 16, 2014 | $40.0M Series B | Bill & Melinda Gates Foundation |